BGJ398 (Infigratinib) is a selective, reversible ATP-competitive pan-FGFR inhibitor. It blocks MAPK/ERK and PI3K/AKT/mTOR signaling by inhibiting FGFR phosphorylation, effectively suppressing tumor cell proliferation, migration, and inducing apoptosis.
BGJ398 (Infigratinib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for BGJ398 (Infigratinib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.